The Glabridin from Huangqin Decoction Prevents the Development of Ulcerative Colitis into Colitis-Associated Colorectal Cancer by Modulating MMP1/MMP3 Activity
International Immunopharmacology · 2024-06 · 135 · 112262
DOI: 10.1016/j.intimp.2024.112262 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-06. Verfasst von Roude Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China; The second school of clinical medicine, Guangdong Medic…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Drugs, Chinese Herbal, Isoflavones, Matrix Metalloproteinase 1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Science and Technology of Guangdong Province, Dongguan Science and Technology Bureau, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
BACKGROUND AND AIM: Huangqin decoction (HQD) is a Chinese medicine used to treat colitis and colorectal cancer (CRC). However, the specific compounds and mechanisms of HQD remain unclear despite its good curative clinical results. Through bioinformatics, network pharmacology, and experiments, this study aims to explore the progressive mechanisms of colitis-associated colorectal cancer (CAC) from ulcerative colitis (UC) while examining the protective effects of HQD and its compounds against this. METHODS: Bioinformatics was utilized to identify the hub genes between UC and CRC, and their clinical predictive significance, function, and expression were validated. Employing network pharmacology in combination with hub genes, key targets of HQD for preventing the development of UC into CAC were identified. Molecular docking and molecular dynamics (MD) were utilized to procure compounds that effectively bind to these targets and their transcription factors (TFs). Finally, the expression and mechanism of key targets were demonstrated in mice with UC or CAC. RESULTS: (1) Joint analysis of UC and CRC gene sets resulted in 14 hub genes, mainly related to extracellular matrix receptor binding, biological processes in the extracellular matrix, focal adhesion and neutrophil migration; (2) Network pharmacology results show HQD has 133 core targets for treating UC and CRC, acting on extracellular matrix, inflammatory bowel disease, chemical carcinogen receptor activation and other pathways; (3) The intersection of hub genes and core targets yielded two key targets, MMP1 and MMP3; (4) STAT3 is a shared TF of MMP1 and MMP3. (5) Molecular docking and MD verified that the dockings between Glabridin and STAT3/MMP1/MMP3 are stable and reliable; (6) In murine vivo experiments verified that Glabridin reduces inflammation, extracellular matrix degradation, and the occurrence of epithelial-mesenchymal transition to prevent UC transforming into CAC by inhibiting the phosphorylation of STAT3 and regulating the activity of MMP1/3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China; The second school of clinical medicine, Guangdong Medical University, Dongguan 523000, China. Electronic address: g_lirid@163…
- The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China; The second school of clinical medicine, Guangdong Medical University, Dongguan 523000, China. Electronic address: chihonggang…
- The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China; The second school of clinical medicine, Guangdong Medical University, Dongguan 523000, China. Electronic address: liewhiuha@1…
- The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China; The second school of clinical medicine, Guangdong Medical University, Dongguan 523000, China. Electronic address: 931015763@q…
- The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523000, China; The second school of clinical medicine, Guangdong Medical University, Dongguan 523000, China; Department of Traditional Chine…
Förderung
- Department of Science and Technology of Guangdong Province
- Dongguan Science and Technology Bureau
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Li, R., Chi, H., Liao, X., Cen, S., & Zou, Y. (2024). The Glabridin from Huangqin Decoction Prevents the Development of Ulcerative Colitis into Colitis-Associated Colorectal Cancer by Modulating MMP1/MMP3 Activity. International Immunopharmacology, 135, 112262. https://doi.org/10.1016/j.intimp.2024.112262
Vancouver
Li R, Chi H, Liao X, Cen S, Zou Y. The Glabridin from Huangqin Decoction Prevents the Development of Ulcerative Colitis into Colitis-Associated Colorectal Cancer by Modulating MMP1/MMP3 Activity. International Immunopharmacology. 2024;135:112262. doi:10.1016/j.intimp.2024.112262
BibTeX
@article{Li2024,
author = {Li, Roude and Chi, Honggang and Liao, Xiaoxia and Cen, Shuimei and Zou, Ying},
title = {The Glabridin from Huangqin Decoction Prevents the Development of Ulcerative Colitis into Colitis-Associated Colorectal Cancer by Modulating MMP1/MMP3 Activity},
journal = {International Immunopharmacology},
year = {2024},
volume = {135},
pages = {112262},
doi = {10.1016/j.intimp.2024.112262}
}
EUVIMED